REG - OptiBiotix Health - Launch of GoFigure range with Apollo Hospitals

OptiBiotix HealthAnnouncement

09/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211209:nRSI0428Va&default-theme=true

RNS Number : 0428V  OptiBiotix Health PLC  09 December 2021

    OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

Launch of GoFigure range with Apollo Hospitals in India

 

OptiBiotix Health India, a wholly owned subsidiary of OptiBiotix Health plc
(AIM: OPTI), a life sciences business developing unique science and human
study-based compounds that modulate the microbiome to address metabolic
syndrome and diabetes, systemic low-grade inflammation, obesity,
cardiovascular disease, high cholesterol and to support healthy aging, has
signed an exclusive sales agreement with one of the leading hospital and
pharmacy chain Apollo Hospitals Enterprises Limited ("Apollo") for the sales
of its GoFigure weight management product range in India.

 

Apollo owns Apollo Pharmacies (https://www.apollopharmacy.in/
(https://www.apollopharmacy.in/) ) which is one of the largest and most
trusted branded pharmacy network, with over 4,000 pharmacy outlets throughout
India. The in-store launch is expected to take place in February 2022 and will
progressively expand from there to other stores as well as online. India is a
region of strategic interest to OptiBiotix with a middle class predicted to be
the largest in the world by 2025 (The rising importance of the middle class in
India - The Financial Express
(https://www.financialexpress.com/opinion/the-rising-importance-of-the-middle-class-in-india/2223544/)
,  March 2021).

 

GoFigure is OptiBiotix's direct-to-consumer (D2C) range of weight management
products which combines various meal replacement and healthy snacking options
including its multi award winning weight management ingredient SlimBiome®.
The initial product launch will consist of meal replacement shakes and
powdered beverages and will be expanded over time.

 

This agreement is part of OptiBiotix' strategy to expand the geographical
footprint of its pro- and prebiotic business with leading brands in the health
& wellness market. It follows the recruitment of Dr Taru Jain as Business
Director India earlier in the year (RNS: 19 January 2021) and the
incorporation of OptiBiotix India in recent weeks (RNS: 17 November 2021).

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased
to announce this agreement with Apollo, a leading pharmacy chain in India. Our
GoFigure range of weight management products have been specifically formulated
to support consumers aiming to reduce their weight and help them stick to
their change in diet. We are very pleased that Apollo has selected GoFigure as
its range of weight management products of choice to offer to its consumers.
This launch is another important step in building sales and brand presence for
OptiBiotix' solutions with major partners around the world."

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07876 741 001
 Anna Dunphy

 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRFLFITFFLTIIL